Objective: To estimate the economic implications of introducing dabigatran etexilate
('dabigatran') for anti-coagulation therapy in Danish patients with non-valvular atrial …

Objective: To assess the cost-effectiveness of dabigatran etexilate ('dabigatran') vs vitamin K
antagonists (VKAs) in the Belgian healthcare setting for the prevention of stroke and …

Dabigatran etexilate is a newly approved agent for prophylaxis of stroke in atrial fibrillation.
Through narrative review, the authors assess evidence of the efficacy of dabigatran in stroke …

This article provides an overview of the clinical profile of oral dabigatran etexilate
(Pradaxa®, Pradax™)[hereafter referred to as dabigatran] when used for the prevention of …

Abstract The National Institute for Health and Clinical Excellence (NICE) invited the
manufacturer of dabigatran etexilate (Boehringer Ingelheim Ltd, UK) to submit evidence for …

Objectives: Atrial fibrillation is a major risk factor for ischemic stroke and anticoagulation
therapy is indicated to reduce risk. Dabigatran is a new oral anticoagulant that does not …

Aims Patients with atrial fibrillation have a significantly increased risk of thromboembolic
events such as ischaemic stroke, and patients are therefore recommended to be treated with …

Oral dabigatran etexilate is indicated for the prevention of stroke and systemic embolism in
patients with atrial fibrillation (AF) in whom anticoagulation is appropriate. Based on the RE …

Background To compare the management cost and cost‐effectiveness of dabigatran with
warfarin in patients with nonvalvular atrial fibrillation (AF) from the hospital's and patients' …

Background. Dabigatran is an oral anticoagulant direct thrombin inhibitor recently registered
in South Africa (SA) to reduce the risk of stroke and systemic embolism in patients with atrial …